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p19ARF and RasV12 Offer Opposing Regulation of DHX33 Translation
To Dictate Tumor Cell Fate
Yandong Zhang, Anthony J. Saporita, Jason D. Weber
BRIGHT Institute and Department of Internal Medicine, Division of Molecular Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis,
Missouri, USA
DHX33 is a pivotal DEAH-box RNA helicase in the multistep process of RNA polymerase I-directed transcription of the ribo-
somal DNA locus. We explored the regulation of DHX33 expression by RasV12 and ARF to determine DHX33’s role in sensing
these opposing signals to regulate ribosome biogenesis. In wild-type primary fibroblasts, RasV12 infection induced a transient
increase in DHX33 protein level, as well as an rRNA transcriptional rate that was eventually suppressed by a delayed activation
of the ARF/p53 pathway. DHX33 expression was exclusively controlled at the level of translation. ARF caused a dramatic reduc-
tion in polysome-associated DHX33 mRNAs, while RasV12 led to a complete shift of existing DHX33 mRNAs to actively translat-
ing polysomes. The translation of DHX33 by RasV12 was sensitive to inhibitors of phosphatidylinositol 3-kinase, mTOR, and
mitogen-activated protein and was pivotal for enhanced rRNA transcription and enhanced overall cellular protein translation.
In addition, DHX33 knockdown abolished RasV12-induced rRNA transcription and protein translation and prevented both the
in vitro and in vivo transforming properties of oncogenic RasV12. Our results directly implicate DHX33 as a crucial player in
establishing rRNA synthesis rates in the face of RasV12 or ARF signals, adjusting ribosome biogenesis to match the appropriate
growth or antigrowth signals.
Cancers frequently harbor genetic mutations that activate on-cogenes or inactivate tumor suppressors, leading to uncon-
trolled cell growth, evasion of apoptosis, and other enhanced cel-
lular properties (1). To accommodate the rapid proliferation of
cancer cells, several associated biological activities are also aug-
mented in cancer cells (2). Recently, increasing evidence has
shown that cancer cells often increase ribosome production to
improve protein translation and cell growth (3–7). Ribosome bio-
genesis is frequently targeted by activated oncogenes and re-
pressed by tumor suppressors (as reviewed in references 3 and 8).
In fact, the link between nucleolar hypertrophy and tumorigenesis
was recognized more than 100 years ago (8, 9). More recent data
indicate that a marked increase in rRNA synthesis is a general
attribute of many cancers (9, 10), which is consistent with the idea
that changes in rRNA synthesis may be prerequisite alteration
in the progression to cellular transformation. The rate of can-
cer cell proliferation in tumors is directly proportional to nu-
cleolar size and RNA polymerase I (Pol I) activity, with over-
expression of pre-rRNA correlating with poor prognosis in
many cancers (10–13).
Ribosome biogenesis largely occurs in the nucleolus and is a
highly coordinated biological process that includes rRNA synthe-
sis, modification, processing, and assembly into ribosome sub-
units (10, 14–16). It is tightly controlled and directly linked to cell
cycle events; defects in ribosome biogenesis often lead to apoptosis
or cell cycle arrest (17–19). The initial step of ribosome biogenesis,
ribosomal DNA (rDNA) transcription, is subject to numerous
layers of regulation (20–22). Human rDNA contains400 copies
of the rRNA genes, organized in tandem arrays on five different
human chromosomes. Initiation of rDNA transcription requires
assembly of a specific multiprotein complex including Pol I and
numerous associated proteins (3, 10). Two of these proteins are
upstream binding factor (UBF) and the promoter selectivity fac-
tor, SL1/TIF-IB. Interaction of these two proteins at rDNA pro-
moter leads to assembly of the preinitiation complex and subse-
quent transcriptional activation at the promoter (15, 23). Given its
extreme importance in initiating ribosome biogenesis, rDNA
transcription is greatly influenced by the Ras, Myc, and NPM on-
cogenes, as well as the ARF, p53, and PTEN tumor suppressors
(14, 16, 24–29).
We previously identified the nucleolar DHX33 DEAH-box
RNA helicase as an important mediator of RNA Pol I transcription
through its interaction with UBF at rDNA loci following serum
stimulation (30). In the present study, we explored the mecha-
nism underlying DHX33 regulation. We now report that DHX33
is positioned at the crossroads of opposing Ras and ARF activities;
oncogenic RasV12 stimulates but ARF represses translation of ex-
isting DHX33 mRNAs. In this manner we show that, DHX33 is
used as an endpoint of contrasting signals to set ribosome biogen-
esis rates. Using xenograft models and established Ras mutant
cancer cell lines, we demonstrate that DHX33 accumulation is
pivotal for RasV12 to initiate tumor formation.
MATERIALS AND METHODS
Cell culture. Wild-type mouse embryonic fibroblasts (MEFs), Arf/ ear
fibroblasts, Arf/ MEFs, p53/ MEFs, p53/; Mdm2/ MEFs, and
p53/; Mdm2/; Arf/ MEFs were isolated from C57BL/6/Sv129
mixed mice. BxPC-3, Capan-2, Miapaca-2, and Panc-1 pancreatic cancer
cell lines were kindly provided by Andrea Wang-Gillam (Washington
University), BeaS2B cells were provided by Gregory Longmore (Washing-
ton University), and H441 and A549 lung cancer cells were provided by
Steven Brody (Washington University). BxPC-3 and H441 cells were
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grown in RPMI 1640 containing 10% fetal bovine serum (FBS) with an-
tibiotics and supplements (10 mmol of HEPES, 4.5 g of glucose, 2 mmol of
L-glutamine, and 1 mmol of sodium pyruvate/liter). A549 cells were
grown in F-12 medium supplemented with 10% FBS and 1% penicillin-
streptomycin. All other cells were maintained in Dulbecco modified Eagle
medium (DMEM) supplemented with 10% FBS and 1% penicillin-strep-
tomycin. All cell lines were incubated at 37°C with 5% CO2 in a humidi-
fied incubator. U0126 and LY294002 were purchased from Sigma. Rapa-
mycin was purchased from LC laboratories.
Western blotting and antibodies. Whole-cell lysates were prepared
by incubation with 1 NP-40 buffer that included 0.5% NP-40 and 1%
sodium dodecyl sulfate (SDS) supplemented with HALT protease and
phosphatase inhibitors (Sigma). Lysates were cleared by centrifugation
and protein concentration was tested by DC assay (Bio-Rad). Lysates were
boiled with SDS sample buffer, separated by SDS-PAGE, and transferred
to polyvinylidene difluoride membrane (Millipore). Membranes were
blocked in 5% nonfat dry milk TBS-T buffer (10 mmol of Tris-HCl [pH
7.4]/liter, 150 mmol of NaCl/liter, 0.1% Tween 20) and incubated in pri-
mary antibodies diluted in blocking buffer at 4°C overnight. Blots were
washed with TBS-T buffer and incubated with horseradish peroxidase-
conjugated secondary antibodies (1:10,000; GE Healthcare) in blocking
buffer at room temperature. Immune complexes were visualized with an
enhanced chemiluminescence kit (GE Healthcare). Primary antibodies
for immunodetection were sourced as follows: anti-ARF (rat; Santa Cruz),
antitubulin (goat; Santa Cruz), anti-DHX33 (Novus), anti-S6 (Cell Sig-
naling), anti-pS6 (Cell Signaling), anti-NF1 (Santa Cruz), anti-Ras (Santa
Cruz), anti-p53 (Cell Signaling), anti-AKT (Cell Signaling), and anti-
pS473-AKT (Cell Signaling).
Quantitative reverse transcription-PCR (qRT-PCR). Primers were
all designed by Primer Express 2.0 software and purchased from Inte-
grated DNA technologies. Total RNA was extracted by NucleoSpin II
(Clontech) RNA isolation kit and was reverse transcribed into cDNA by
SuperScript III first-strand synthesis kit (Invitrogen). PCRs were per-
formed on Bio-Rad C1000 thermal cycler and managed with Bio-Rad
CFX96 software. For analysis of 47S rRNA transcript levels, SYBR green
FastMix (Quanta Biosciences) was used and transcript quantification was
performed by comparison with standard curves generated from dilution
series of cDNA of human 47S rRNA (cloned in pCR2.1Topo). SYBR green
mix from Bio-Rad was used for all other qRT-PCR analysis. Transcript
quantification was calculated based on the value of CT after normal-
ization to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) values.
Melting curve analysis confirmed that single products were amplified.
Focus assay. Human cancer cell lines were infected by pLKO.1 lenti-
virus encoding shScrambled RNA or shRNA to knockdown DHX33, and
cells were selected by puromycin for 2 days. Cells were then plated at a
density of 104 per 100-mm dish and grown for 10 to 20 days. Colonies
were washed with cold phosphate-buffered saline twice and fixed with
100% methanol for 10 min at room temperature. Colonies were then
stained with Giemsa stain for 1 h at room temperature and washed with
water before air-dried and photographed.
Soft agar assay. A total of 104 cells were mixed in 4.0 ml of 0.3%
agar–1 DMEM–10% FBS as the top agar and plated into 60-mm plates
with 4.0 ml of 0.6% agar–1 DMEM–10% FBS as the base agar. Plates
were incubated at 37°C and checked every 3 days, and the cells were fed
with 2.0 ml of 0.3% agar–1DMEM–10% FBS every week. The colonies
were photographed and counted 2 to 3 weeks later.
Polysome profiles. Cells (3  106) after transduction with the indi-
cated virus for 96 h were treated with 10 g of cycloheximide/ml prior to
harvesting and counting. Cells were subjected to cytoplasmic ribosome
fractionation as described previously using a sucrose density gradient sys-
tem ranging from 7 to 47% (Teledyne ISCO). Fractions were collected,
and RNA was extracted with TRIzol and converted into cDNA with su-
perscript reverse transcriptase III (Invitrogen) before quantitative PCR
analysis with the appropriate primers.
[3H]uridine pulse-chase labeling. Cells were first infected with the
indicated virus. At 3 days postinfection, the cells were replated at a con-
fluence of 60 to 70% per plate. On the following day, the cells were then
pulsed with [3H]uridine at a concentration of 2.5 Ci/ml for 30 min and
chased with unradiolabeled uridine at a concentration of 5 mM for the
indicated time points. Approximately 2 106 cells were pelleted, and the
total RNA was isolated after dissolving cells in RNAsolv (Omega Biotek,
Norcross, GA). Formaldehyde RNA denaturing gel was run to separate
different species of rRNA and then transferred to nylon Hybondmem-
brane. After UV cross-linking and spraying with Enhancer (Perkin
Elmer), the membrane was exposed to film and subjected to autora-
diography.
[35S]methionine incorporation. Cells were starved in cysteine-methi-
onine-free medium for 4 h and then pulsed with [35S]methionine (50
Ci/ml)-containing medium for 30 min before being harvested. The cells
were lysed, and supernatants were precipitated with trichloroacetic acid at
a concentration of 10%. Protein pellets were subsequently dissolved by
1% SDS and analyzed for protein concentration. The samples were then
analyzed for radioactivity by liquid scintillation counting. The data pre-
sented were normalized based on equal amount of protein in each sample.
Mouse xenografts. Animals were handled according to protocols ap-
proved by the Washington University Animal Studies Committee. Nude
mice were purchased from Jackson laboratories. Arf-null cells after trans-
duction with the indicated virus were injected subcutaneously with 106
cells into the flanks of mice. Tumors were dissected after 2 weeks and
photographed.
RESULTS
p19ARF induction during oncogenic stress lowers DHX33 pro-
tein levels. ARF is the principal tumor surveillance protein charge
with preventing aberrant cell growth and proliferation during on-
cogenic insult (18, 31). In wild-type primary fibroblasts, onco-
genic RasV12 induces ARF protein expression, resulting in subse-
quent p53 activation and cell cycle arrest. Numerous tumor
suppressers and oncogenes are known to influence the levels and
activities of key molecules involved in rDNA transcription, sug-
gesting that rRNA transcription might be a focal point of opposing
signaling moieties (3). Previously, we have shown that the DHX33
DEAH RNA box helicase is a novel regulator of rRNA transcrip-
tion (30). To test whether p19ARF and RasV12 could affect DHX33
expression, wild-type (WT) MEFs were infected with either con-
trol, RasV12, or ARF-expressing retroviruses. DHX33 protein lev-
els were analyzed at 2, 3, or 5 days postinfection. As shown, the
ectopic expression of ARF resulted in a significant decrease in the
DHX33 protein expression 2 days postinfection (Fig. 1A). Reduc-
tion of DHX33 by ARF continued through 3 days postinfection,
when the DHX33 protein levels decreased 10-fold (Fig. 1B). In
contrast, oncogenic stress by RasV12 infection resulted in slightly
more DHX33 protein than control cells at 2 and 3 days postinfec-
tion (Fig. 1A and B). Noticeably, upregulation of ARF and p53
were only modest at these early time points following ectopic
RasV12 expression. However, after 5 days of RasV12 infection, wild-
type primary cells expressed significant levels of ARF with a resul-
tant decrease in DHX33 protein (2-fold reduction) compared to
control cells (Fig. 1C). These results indicate that two major path-
ways might regulate DHX33: ARF/p53 and oncogenic RasV12. The
opposing activities from these two pathways caused DHX33 levels
to be transiently increased and then significantly decreased. In
accordance with this hypothesis, RasV12 infection of fibroblasts
deficient in ARF (Arf-null MEFs) resulted in a robust increase in
DHX33 levels from 2 days until 6 days postinfection (Fig. 1D).
This is in contrast to a 2-fold reduction of DHX33 in WT MEFs in
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which endogenous ARF function is intact and induced during
RasV12 infection. Thus, our results indicate that endogenous ARF
is a key regulator of DHX33 expression during oncogenic stress.
We next performed quantitative real-time PCR (qRT-PCR) to
determine ribosome RNA transcriptional rates by analyzing 47S
pre-rRNA transcript levels in both RasV12 and ARF-infected wild-
type MEFs. As shown in Fig. 1E, ARF infection resulted in the
downregulation of rRNA transcription in a time-dependent man-
ner. At 5 days postinfection, 47S rRNA levels dropped to 30% of
that in the control sample. Moreover, RasV12 infection first re-
sulted in a transient increase in pre-rRNA synthesis at 2 and 3 days
postinfection (up to 2.5-fold), but after 5 days postinfection, after
endogenous ARF induction, the pre-rRNA levels dropped to 70%
of empty vector control (Fig. 1E). This trend is in agreement with
the increase in DHX33 followed by its decrease over time after
RasV12 infection.
ARF regulation of DHX33 is dependent on Mdm2 and p53.
The ARF tumor suppresser has p53-dependent and -independent
FIG 1 Regulation of DHX33 during oncogenic stress. (A) Wild-type MEFs were infected with retroviruses encoding RasV12, p19ARF, or empty vector, whole-cell
lysates were prepared at 2 days postinfection and were subjected to Western blot analysis with the indicated antibodies. (B) The above-mentioned cells were
harvested 3 days postinfection, and whole-cell extracts were subjected to Western blot analysis with the indicated antibodies. (C) Wild-type MEFs were infected
with retroviruses encoding RasV12 or empty vector, whole-cell extracts were prepared 5 days postinfection and were subjected to Western blot analysis with the
indicated antibodies. (D)Arf-null MEFs were infected with retroviruses encoding RasV12 or empty vector, whole-cell extracts were prepared from 2 days till 6 days
postinfection and were subjected to Western blot analysis with the indicated antibodies. (E) Wild-type MEFs were infected with the above-mentioned retrovi-
ruses, and total RNA was extracted at 2, 3, or 5 days postinfection. Mouse 47S pre-rRNA levels were analyzed by real-time PCR and graphed in a time-dependent
manner. Changes in DHX33 protein levels in the time course were also graphed after quantitation of DHX33 signals in panels A to C after normalization to the
empty vector control. Error bars were taken from three independent experiments.
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functions (32). Wild-type MEFs maintain an intact p53 pathway
downstream of ARF, suggesting that regulation of DHX33 by ARF
in WT MEFs could be p53 dependent. To study whether this reg-
ulation occurs in a p53-dependent manner, we infected p53/
MEFs, p53/; Mdm2/ (DKO) MEFs, and p53/; Mdm2/;
Arf/ (TKO) MEFs with ARF-expressing retroviruses. As shown
in Fig. 2, ARF overexpression in WT MEFs resulted in a significant
reduction in DHX33 levels. However, the reduction of DHX33
was far less significant in p53-null MEFs and DKO MEFs. In TKO
MEFs, we observed no reduction in DHX33 protein levels, indi-
cating that reduction of DHX33 by ARF requires p53 (Fig. 2B). In
addition, we found that the infection of ARF in wild-type MEFs
resulted in a much greater inhibition of ribosome RNA synthesis
than in TKO MEFs (Fig. 2C). Our results indicate that ARF inhib-
its ribosome biogenesis not only in a p53-independent manner
but also in a p53-dependent manner. Knockdown of endogenous
ARF only mildly enhanced DHX33 protein expression in p53/
MEFs (Fig. 2D), suggesting that p53 is required for DHX33 induc-
tion following loss of ARF.
ARF reduces DHX33 protein levels through a translational
control mechanism. To dissect the mechanism of DHX33 reduc-
tion by ARF, we first analyzed DHX33 mRNA levels. qRT-PCR
FIG 2 Reduction of DHX33 by ARF infection is dependent on p53 and Mdm2. (A) Wild-type MEFs, p53-null MEFs, p53/; Mdm2/ MEFs, and p53/;
Mdm2/; Arf/ MEFs were infected with retroviruses encoding either pBABE empty vector or pBABE-HA-ARF. Whole-cell lysates were prepared 5 days
postinfection and were subjected to Western blot analysis by the indicated antibodies. (B) Quantitation of the DHX33 protein levels after normalization to empty
vector in each group, error bars were taken from three independent experiments. (C) MEFs were infected by retrovirus encoding pBABE empty vector or
pBABE-HA-ARF. At 4 days postinfection, cells were harvested and analyzed by Western blotting with the indicated antibodies. At 4 days postinfection, cells were
also pulsed by [3H]uridine and chased at the indicated time points. Total RNA were analyzed for 47S pre-rRNA levels. (D) WT MEFs or p53-null MEFs were
infected with lentivirus encoding either shSCR or shARF. At 4 days postinfection, the cells were harvested and subjected to Western blot analysis with the
indicated antibodies.
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was performed on total RNAs isolated from ARF- and RasV12-
infected cells at 2, 3, and 5 days postinfection. Both GAPDH
mRNA and actin mRNAs were used as internal controls. We ob-
served no significant change in DHX33 mRNA expression at each
time point after ARF or RasV12 infection of WT MEFs compared to
the empty vector control (Fig. 3A). These results indicate that
reduction of DHX33 by ARF does not occur by transcriptional
regulation. ARF has been previously shown to influence the sta-
bility of several proteins (33, 34). To determine whether DHX33
protein reduction was due to accelerated protein degradation
upon ARF induction, cells were treated with MG132, a 26S pro-
teasome inhibitor, for 6 h. As shown in Fig. 3B, we found that
DHX33 was not stabilized in the presence of MG132. As a positive
control, p21CIP1 was stabilized to a significant degree with MG132
treatment, demonstrating that MG132 is functioning as expected
to inhibit 26S proteasome. These results imply that reduction of
DHX33 in the presence of ARF is not due to accelerated protein
degradation.
To determine whether DHX33 reduction was due to transla-
tional repression of existing DHX33 mRNAs, we chose to analyze
polysome-associated DHX33 mRNAs. We performed a polysome
fractionation by sucrose gradient after lysis of WT MEFs that were
either transduced with vector control or ARF overexpressing ret-
roviruses (Fig. 3C). We analyzed the mRNA distribution of
DHX33 in monosome and polysome fraction by qRT-PCR. As
shown in Fig. 3D, we found that in ARF-infected WT MEFs, a
large portion of DHX33 mRNAs (up to 60% of total mRNA) had
moved into the monoribosome fractions. Conversely, empty vec-
tor-infected WT MEFs exhibited a majority of their DHX33
mRNAs associated with polysomes (70%). These data clearly in-
FIG 3 Induction of ARF inhibits DHX33 translation. (A) Wild-type MEFs were infected with retroviruses encoding empty vector, p19ARF, or RasV12, and the
total RNA was extracted from each sample at 2, 3, or 5 days postinfection. DHX33 mRNA levels were analyzed by qPCR with GAPDH as an internal control. Bars
represent the standard deviation taken from three separate experiments. (B) Wild-type MEFs were infected with retroviruses encoding empty vector (EV) or
p19ARF. At 3 days postinfection, the cells were treated with 50M MG132 for 6 h, and total cell lysates were prepared and subjected to Western blot analysis with
the indicated antibodies. p21 protein stabilization was used as a positive control to monitor MG132 function. (C) A total of 1.5 106 wild-type cells infected with
retroviruses encoding empty vector or p19ARF at 3 days postinfection were subjected to cytosolic polysome fractionation. The absorbance was monitored at 254
nm, and resultant ribosome profiles are shown for each sample. (D) The above-mentioned fractions from monoribosomes or polysomes were subjected to total
RNA isolation and qPCR analysis to detect DHX33 mRNA levels. GAPDH mRNA levels were used as a control. The data presented are the percentages of mRNA
from each fraction calculated from a standard curve generated by a series of diluted DHX33 plasmid. Error bars were taken from two independent experiments.
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dicate that ARF induction causes a translational repression of
DHX33 in the cytoplasm.
DHX33 protein reduction decreases protein translation, while
DHX33 overexpression enhances protein translation. Our previ-
ous data has shown that DHX33 is an important regulator of
rRNA transcription; DHX33 knockdown reduced rRNA produc-
tion, while DHX33 overexpression enhanced rRNA synthesis
(30). In TKO MEFs, we manipulated DHX33 levels by utilizing
lentivirus infection to knockdown (Fig. 4A) or overexpress
(Fig. 4E) DHX33 protein. As shown in Fig. 4B, knockdown of
DHX33 nearly abolished all rRNA production. Since rRNA is the
key component for ribosome assembly, we hypothesized that
DHX33 knockdown should result in less available ribosomes and
thus decrease overall protein translation. mRNAs undergoing ac-
tive translation are bound to multiple ribosomes, forming poly-
somes. The level of polysomes is widely regarded as an indicator of
overall protein translational activity. Therefore, we performed cy-
tosolic ribosome fractionation using sucrose gradients to monitor
polysome levels. Strikingly, we noted a significant reduction of
polysomes in TKO MEFs infected with DHX33 knockdown lenti-
viruses (Fig. 4D). The cytosolic 40S and 80S ribosomes were also
decreased dramatically. Interestingly, the 60S ribosome peak was
enhanced, indicating a different dynamic regulation of 40S and
60S, even though all of the rRNA species were decreased signifi-
cantly (Fig. 4C).
Previously, we have found that wild-type DHX33 overexpres-
sion enhanced rRNA synthesis, while helicase-defective mutant
of DHX33 (K94R) inhibited it (30). To determine the effect of
DHX33 overexpression on cell growth, we transduced wild-type
DHX33 and helicase-dead K94R mutant of DHX33 in TKO MEFs
FIG 4 DHX33 protein knockdown or overexpression influences ribosome biogenesis and protein translation. (A) Arf/p53/Mdm2/ MEFs were infected by
lentivirus encoding shRNA-DHX33 or shScrambled (shSCR). At 3 days after infection, the cell lysates were subjected to Western blot analysis with anti-DHX33
and tubulin antibodies. (B) Infected cells from above were pulsed with [3H]uridine and chased for the indicated time points to monitor newly synthesized rRNA.
Equal numbers of cells were pelleted for total RNA extraction. RNA was separated and transferred onto nylon membranes for autoradiography. (C) Equal
numbers of the above-mentioned cells were subjected to total RNA isolation and then isolated by formaldehyde RNA denaturing gel. 28S and 18S rRNA were
visualized by ethidium bromide staining and quantified. Bars were taken from three different experiments. (D) Equal numbers of Arf/p53/Mdm2/ MEFs
infected by the indicated short-hairpin lentiviruses were subjected to cytosolic ribosome profile analysis at 4 days postinfection. (E and F) Arf/p53/Mdm2/
MEFs were infected with lentiviruses encoding empty vector, DHX33 (wild type) or mutant DHX33 (K94R). At 4 days postinfection, infected cells were subjected
to cytosolic polysome profile analysis (E) and Western blot analysis with the indicated antibodies (F).
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by lentivirus infection. Wild-type DHX33 only slightly enhanced
80S formation and polysome formation, whereas the K94R
DHX33 mutant resulted in decreased levels of polysomes
(Fig. 4E). This suggests that DHX33 is important for translation,
but its overexpression might not be sufficient to significantly en-
hance protein synthesis. Western blot analysis showed levels of
overexpressed wild-type and K94R mutant DHX33 (Fig. 4F).
RasV12 stimulates DHX33 mRNA translation. We previously
showed that RasV12 expression caused a significant increase in
DHX33 protein expression in Arf-null MEFs, implying that Ras
hyperactivation regulates DHX33 levels in the absence of Arf. The
neurofibromin (Nf1 gene) tumor suppressor protein is an up-
stream regulator of Ras signaling; loss of Nf1 results in irreversible
activation of Ras and results in subsequent heightened growth and
proliferation in vitro and in vivo tumor formation (35–37). We
isolated MEFs from Nf1fl/fl mice and used adenovirus to overex-
press Cre recombinase, resulting in the successful deletion of Nf1
alleles (Fig. 5A). Compared to the control Lac Z adenovirus-in-
fected Nf1fl/fl MEFs, we found that DHX33 was upregulated 2.7-
fold following Nf1 loss (Fig. 5A). As a confirmation for the activa-
tion of Ras signaling, we also detected increased levels of
phospho-S6 and phospho-AKT (Fig. 5A).
In order to dissect the mechanism of DHX33 induction by Ras
signaling, we first confirmed the activation of several conserved
signaling events downstream of Ras. As shown in Fig. 5B, RasV12
expression in Arf-null cells induced activation of the mitogen-
activated protein kinase (MAPK) pathway as indicated by in-
creased phospho-ERK1/2 and activation of phosphatidylinositol
FIG 5 Ras activity induces DHX33 protein expression. (A) Nf1fl/fl MEFs were infected with adenoviruses encoding either LacZ or Cre recombinase at a
multiplicity of infection of 200. At 2 days postinfection, the cells were then serum starved for 72 h. Equal amount of cell lysates were subjected to Western blot
analysis with the indicated antibodies. (B) Arf-null ear fibroblasts from 2-month-old mice were infected with retroviruses encoding either pBABE empty vector
(EV) or pBABE-RasV12. At 3 days postinfection, infected cells were subjected to Western blot analysis with the indicated antibodies. (C) The above-mentioned
cells were treated with cycloheximide at a concentration of 80g/ml for the indicated times. Protein extracts from the cells pelleted from the indicated time points
was subjected to Western blot analysis. Signals of DHX33 protein was graphed after normalization to GAPDH control. Bars represent errors from two
independent experiments. (D) Total RNA was isolated from the above-mentioned cells and changes of DHX33 mRNA levels were analyzed by qPCR with
GAPDH as a control. P is derived from five separate experiments. (E) Arf-null ear fibroblasts were infected with empty vector or RasV12. At 3 days postinfection,
the cells were treated with U0126 (20 M), wortmannin (100 nM), or LY294002 (50 M) for 24 h. Cell lysates were subjected to Western blot analysis with the
indicated antibodies. (F) Arf-null cells infected with empty vector or RasV12 were treated with rapamycin, wortmannin, or LY294002 as indicated for 24 h. Cell
lysates were prepared and analyzed for DHX33 protein levels with GAPDH as a loading control. (G) Arf-null MEFs were infected with retroviruses encoding
myristoylated Akt (Myr-Akt), RasV12, or empty vector. Cell lysates were prepared at 4 days postinfection after puromycin selection and analyzed by Western
blotting for DHX33, pAkt-473, Akt, and GAPDH protein levels. The fold change is indicated below identified blots.
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3-kinase (PI3K)/AKT pathway as indicated by phospho-AKT-
S473, as well as activation of mTOR pathway by increased phos-
pho-S6. To check whether upregulation of DHX33 in this setting
was due to protein stability or mRNA level changes, we per-
formed protein half-life assays. As shown in Fig. 5C, there was
no significant change in DHX33 stability in empty vector or
RasV12-transduced cells. Next, we analyzed mRNA levels of
DHX33 by RT-PCR and found no significant change in DHX33
mRNA in RasV12-infected cells (Fig. 5D). To dissect the mecha-
nism of DHX33 induction by Ras, we treated RasV12-infected Arf-
null cells with PI3K/AKT or MAPK pathway inhibitors. Upregu-
lation of DHX33 was completely abolished by the PI3K pathway
inhibitors wortmannin and LY294002 but only partially by MEK
inhibitor U0126 (Fig. 5E), demonstrating that Ras/PI3K is the
main signaling pathway that regulates DHX33 protein induction.
To determine whether DHX33 upregulation was controlled by
mTOR activation, we treated cells with rapamycin. As shown in
Fig. 5F, rapamycin inhibited the induction of DHX33 in a dose-
dependent manner to a similar extent as wortmannin and
LY294002, indicating that the Ras/PI3K/mTOR pathway is primarily
responsible for upregulating DHX33 translation. To further confirm
these results, we infected Arf-null MEFs with a constitutively active
myristoylated Akt (Myr-Akt) retrovirus and found that activation of
Akt alone was able to induce DHX33 protein levels but not to the
levels seen in RasV12-infected cells (Fig. 5G).
We also analyzed DHX33 mRNA distribution on polysomes.
As expected, RasV12 infection significantly enhanced production
of cytosolic ribosomes and polysome formation (Fig. 6A). Ap-
proximately 70% of DHX33 mRNA was not associated with poly-
somes in Arf-null cells (Fig. 6B). In contrast, a majority (75%) of
DHX33 mRNAs associated with polysomes in Arf-null cells that
were infected with RasV12 retroviruses (Fig. 6B). As a control,
GAPDH mRNA distribution was also analysis and showed no sig-
nificant difference between empty vector and RasV12 infection
(Fig. 6B). This significant difference shows that DHX33 mRNAs
are selectively translated upon RasV12 infection in the absence of
Arf. To confirm that the Ras/PI3K/mTOR pathway indeed trans-
lationally regulates DHX33, we further treated the cells with rapa-
mycin and analyzed DHX33 mRNA distribution on polysomes.
As shown in Fig. 6C and D, rapamycin treatment resulted in a
reduction of DHX33 protein levels and global protein transla-
tional repression. A significant proportion of DHX33 mRNA was
shifted from polysomes to monoribosomes following rapamycin
treatment (Fig. 6E).
DHX33 upregulation is required for enhanced rRNA tran-
scription during Ras activation. We have previously reported
that DHX33 is an important factor in rRNA transcription (30).
We hypothesized that elevated levels of DHX33 during Ras acti-
vation are important for Ras to promote rRNA synthesis. To test
this hypothesis, we first detected pre-rRNA transcript levels by
qRT-PCR in both empty vector and RasV12-infected Arf-null cells
and saw a 2- to 3-fold increase in 47S rRNA levels (Fig. 7A). To test
whether DHX33 was required for this observed increase in pre-
rRNA levels, Arf-null fibroblasts were first infected with RasV12
retroviruses, followed by a second infection with lentiviruses ex-
pressing knockdown shRNAs for DHX33 (Fig. 7B). We per-
formed pulse-chase labeling with [3H]uridine to detect ongoing
rRNA synthesis. We found that reduction in DHX33 resulted in
significantly lower 47S rRNA transcript levels that mirrored those
seen in uninfected Arf-null cells (Fig. 7C). We also measured
global protein synthesis by [35S]methionine incorporation into
newly synthesized proteins for RasV12 transformed Arf-nulls cells
after DHX33 knockdown and found that DHX33 knockdown
caused a significant reduction in protein synthesis (Fig. 7D).
DHX33 is required in RasV12-initiated tumor formation.
Given that we have shown a requirement for DHX33 in RasV12-
initiated 47S rRNA transcription, we next sought to determine the
contribution of DHX33 to RasV12-driven cellular transformation.
Arf-null MEFs infected with RasV12 retroviruses were subjected to
a second infection with shSCR or shDHX33 lentiviruses. DHX33
protein knockdown efficiency was analyzed by Western blotting
(Fig. 8A). Importantly, DHX33 knockdown did not reduce
DHX33 levels below those seen in control cells (Fig. 8A, lanes 1
and 4). After DHX33 knockdown, cells were plated in soft agar
and grown for 2 weeks and resultant transformed cell colonies
were counted. We observed a significant decrease in soft agar col-
onies in RasV12shDHX33-infected cells, underscoring the im-
portance of heightened DHX33 expression in RasV12-mediated
cellular transformation (Fig. 8B). We next determined whether
DHX33 knockdown influenced RasV12-initiated mRNA transla-
tion. Again, Arf-null MEFs were infected with RasV12 retroviruses
and subjected to a second infection with lentiviruses encoding
shRNAs for DHX33. Western blot analysis confirmed successful
overexpression of RasV12 and knockdown of DHX33 (Fig. 8C).
We measured significant decreases in cytosolic ribosome subunits
and actively translating polysomes in the RasV12shDHX33 cells
(Fig. 8D), indicating that elevated DHX33 expression is required
for enhanced ribosome production and mRNA translation fol-
lowing ectopic RasV12 expression. To assess the impact of DHX33
knockdown on RasV12-initiated tumor formation, we injected
106-infected cells into the flanks of immunocompromised mice.
At 2 weeks postinjection, we detected significant tumor cell
growth of the cells infected with RasV12shSCR, while cells in-
fected with RasV12shDHX33 did not exhibit any measurable tu-
mor formation (Fig. 8E). This striking difference indicates that
DHX33 is a crucial target of oncogenic RasV12 and is required to
enhance RasV12-mediated cell growth and tumor formation.
Correlation between DHX33 protein levels, 47S rRNA levels,
and cell proliferation in K-Ras mutated human cancer cell lines.
Ras gene mutation has been frequently observed in human can-
cers (23). To determine whether endogenous DHX33 is upregu-
lated in human cancers harboring mutant Ras alleles, we per-
formed Western blot analysis for endogenous DHX33 protein
levels on a panel of human cancer cell lines. As shown in Fig. 9A,
we found elevated DHX33 protein levels in three of five K-Ras
mutant cancer cell lines using wild-type K-Ras cell lines as a com-
parison. DHX33 protein levels were significantly upregulated in
Miapaca-2, PANC-1, and A549 cells compared to wild-type K-Ras
human cancer cell line, BxPC-3 or normal immortalized human
lung epithelial cell line, BeaS-2B (Fig. 9A). Due to the pivotal role
of DHX33 in rRNA transcription, we also measured 47S rRNA
levels by qRT-PCR in a panel of K-Ras mutated cancer cell lines.
We discovered that 47S rRNA transcript levels correlated with
DHX33 protein levels (Fig. 9B). For example, 47S rRNA transcript
levels were the highest in Miapaca-2 cells, where DHX33 protein level
was also the highest. Although in Capan-2, where DHX33 levels were
the lowest, 47S rRNA level were also the lowest (Fig. 9B). Moreover,
we also noticed that cell proliferation rates were tightly correlated
with DHX33 protein levels and 47S rRNA levels in these K-Ras mu-
tated human cancer cell lines (Fig. 9C).
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To study the importance of DHX33 protein upregulation
in K-Ras mutated human cancer cells, we utilized two unique
shRNAs to knock down endogenous human DHX33 protein lev-
els and measured cell growth over time. The knockdown efficiency
of DHX33 for all five different cancer cell lines is shown in Fig. 9D.
All cells exhibited some dependency on DHX33 for sustained pro-
liferation (Fig. 9E). However, the negative impact of DHX33 on
long-term proliferation was the most dramatic in the highly pro-
liferative Miapaca-2 and A549 cells. The p53 mutational status
might influence the different outcomes we observed for DHX33
knockdown. DHX33 knockdown in Miapaca-2 (mutant p53) re-
sulted in significant cell death, while in p53 wild-type A549 cells,
DHX33 knockdown resulted in a G2/M arrest (Fig. 9F). Taken
together, our results show that elevated DHX33 protein expres-
sion in mutant K-Ras cancer cell lines is pivotal in enhancing
rRNA transcription and proliferation.
DISCUSSION
Ras is one of the most frequently mutated oncogenes in human
cancers. Three members of the Ras family, sharing 85% primary
sequence identity, have been found to be activated in human can-
cers: H-Ras, N-Ras, and K-Ras (25). Up to 30% of human lung
cancers harbor K-Ras mutations and, in pancreatic cancers, the
K-Ras mutation rate is 90% (25). Ras signaling is a complex
FIG 6 DHX33 protein induction is under translational control. (A) A total of 3 106 Arf-null cells infected with retroviruses encoding empty vector or RasV12
at 4 days postinfection were subjected to cytosolic ribosome profiling. (B) The resultant fractionations from above were analyzed by RT-PCR for DHX33 mRNA
distribution on ribosomes. GAPDH was used as a negative control. Bar data were taken from three independent experiments. (C) RasV12-infected Arf-null cells
at 4 days postinfection were treated with rapamycin at 100 nM for 24 h. Whole-cell extracts were then subjected to total protein analysis by Western blotting with
the indicated antibodies. The fold change is indicated underneath the blots. (D) A total of 3 106 of RasV12-infectedArf-null cells after rapamycin treatment (100
nM) were subjected to cytosolic ribosome profiling. (E) The resultant fractions from above were analyzed by RT-PCR for DHX33 mRNA distribution on
ribosomes. GAPDH was used as a negative control. The data represents a typical result from three independent experiments.
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network whose downstream components play multiple roles in
cell growth and cell proliferation. In its active, GTP-bound state,
Ras is able to activate two major oncogenic signaling cascades:
Raf/MEK/ERK and PI3K/AKT pathway (28). Aside from its role in
promoting cell proliferation and cell survival, cell invasiveness
and enhanced production of angiogenic factors, Ras activation
also causes a significant elevation in the production of rRNA and
increases in mRNA translation. Ras enhanced ribosome RNA syn-
thesis are due to a variety of contributions from several Ras down-
stream effectors such as ERK (38–40), cyclin D1 (41, 42), and
mTOR (43, 44), all of which can promote RNA Pol I transcription
through different mechanisms. However, these enhancements
and gains were observed in cells lacking an intact ARF/p53 path-
way. The canonical roles of the ARF tumor suppressor reside in its
ability to sense activated Ras alleles and prevent downstream cel-
lular processes normally augmented by oncogenic Ras. Thus, it
seems that proteins central to these processes must be under the
control of both ARF and Ras regulators. Identifying these key
players was our focus.
In this report, we identified a new downstream target of Ras,
the DHX33 DEAH-box RNA helicase. DHX33 plays as an impor-
tant role in promoting rRNA synthesis and ribosome biogenesis
(30). In cells that maintain an intact Arf locus, oncogenic RasV12
overexpression resulted in a significant reduction in DHX33 pro-
tein expression without any lowering of DHX33 mRNA. The tim-
ing of DHX33 downregulation coincided with the classical induc-
tion of ARF expression by oncogenic RasV12 alleles. This negative
regulation was not observed in cells lacking p53, arguing that the
attenuation of DHX33 protein expression relied on the canonical
ARF/p53 tumor suppressor pathway. Our results support the no-
tion that other than cell cycle regulation, a p53-dependent role of
ARF might also reside in inhibiting ribosome biogenesis. The ARF
tumor suppressor has been found to inhibit rRNA synthesis (14,
24) through its ability to prevent UBF phosphorylation (24) and
by translocating TTF-I, a RNA polymerase I termination factor,
from the nucleolus into the nucleus (31). Nonetheless, in the ab-
sence of Arf, RasV12 was quite capable of dramatically increasing
DHX33 protein expression, squarely placing DHX33 in the nexus
FIG 7 DHX33 protein induction plays a crucial role in RasV12-enhanced rRNA transcription. (A) Arf-null ear fibroblasts from 2-month-old mice were infected
with either empty vector or RasV12-encoding retroviruses. Total RNA was extracted and analyzed by RT-PCR for 47S pre-rRNA levels. Error bars indicate
standard deviation from three independent experiments. (B, C, and D) Arf-null ear fibroblasts were infected with retroviruses encoding empty vector or RasV12.
At 2 days postinfection, the cells were then infected with lentiviruses encoding shScrambled (SCR) or shRNA-DHX33 for 3 days. Cells were then subjected to
Western blot analysis for DHX33 protein levels (B). Equal numbers of cells were pulsed with [3H]uridine and chased at the indicated time points, the total RNA
was isolated and separated for rRNA synthesis analysis, and a representative result from three independent experiments is shown (C). The cells were then
pulse-labeled with [35S]methionine incorporation and 35S-labeled proteins were measured. Error bars represent the standard deviation from three independent
experiments (D). **, P 0.001.
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of ARF and Ras regulation. In contrast to ARF, RasV12 consider-
ably shifted existing DHX33 mRNAs onto translating polysomes.
Thus, we have identified a new route through which ARF inhibits
rRNA synthesis.
We have provided evidence that elevated expression of DHX33
is critical for RasV12-induced cellular transformation. Impor-
tantly, our experiments utilized shRNAs that target and reduce
DHX33 expression back to just above baseline. As such, we are not
entirely removing DHX33 from these cells. Reduction of DHX33
in RasV12-expressing Arf-null cells resulted in a return of 47S
rRNA and mRNA translation back to levels normally seen in Arf-
null cells. These cells no longer grow in soft agar and do not form
tumors in immunocompromised mice. Much of the focus on ARF
tumor biology has been on its ability to respond to oncogenic
signals, such as those emanating from RasV12, to induce a potent
p53-dependent cell cycle arrest. Even more recently, a significant
amount of interest has also shifted to ARF’s ability to directly
inhibit ribosome biogenesis independent of p53. Our new find-
FIG 8 DHX33 induction is required for RasV12-initiated tumor formation. (A) Arf-null ear fibroblasts from 2-month-old mice were infected with retroviruses
encoding pBABE-empty vector (EV) or pBABE-RasV12. Cells were then infected with lentiviruses encoding shScrambled (shSCR), shLuciferase (shLuc), or
shDHX33. Whole-cell lysates were extracted and analyzed by Western blotting with Ras, DHX33, and tubulin antibodies. (B) A total of 5 103 infected cells were
plated onto soft agar 60-mm plates in triplicate to measure anchorage-independent cell growth after 14 days. Quantitation of the colony numbers is presented
from three representative fields under4 magnification. Error bars represent the standard deviation calculated from three different fields of colonies on triplicate
plates. (C) Arf-null NIH 3T3 cells were infected with retroviruses encoding RasV12, followed by infection with lentiviruses encoding shScrambled (shSCR) or
shDHX33. Whole-cell lysates were subjected to Western blot analysis with Ras, DHX33, and tubulin antibodies. (D) A total of 3 106 infected NIH 3T3 cells were
subjected to cytosolic ribosome profiles. (E) The upper panel shows NIH 3T3 cells infected with retroviruses encoding RasV12 that were then infected with shSCR
or shDHX33 lentiviruses. A total of 106 infected NIH 3T3 cells were injected into the flanks of nude mice. Tumor formation was visualized and photographed
after 14 days. For the lower panel, mice were sacrificed at day 14 postinjection, and tumors were excised and photographed.
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ings herein imply that ARF and Ras are in a constant struggle for
downstream target activation/inactivation. Normal cells harbor-
ing activated Ras alleles in the face of wild-type ARF are unable to
gain access to critical downstream targets, such as DHX33, to fully
activate critical processes required for tumorigenesis. ARF effec-
tively eliminates these proteins by removing their mRNAs from
actively translating polyribosomes. When Arf is lost, Ras gains
access to these targets, and active translation of them ensues. How
ARF might selectively repress mRNA translation remains to be
investigated, but our findings with DHX33 are reminiscent of
ARF’s regulation of VEGFA translation (45).
Enhanced ribosome biogenesis is tightly correlated with en-
hanced cell proliferation in human cancers. Targeting RNA Pol I
transcription has been regarded as a potential treatment for cancer
FIG 9 DHX33 is overexpressed in Ras-mutated cancer cell lines and is required for their efficient growth and proliferative properties. (A) A panel of K-Ras
mutated or wild-type cancer cell lines (mutation status is shown at the bottom) were screened for total DHX33 protein expression, p14ARF status is also shown
at the bottom. (B) 47S rRNA was measured by RT-PCR and normalized to total RNA levels. Error bars represent the standard deviation from three separate
experiments. *, P 0.001. (C) A total of 5 104 cells were plated onto six-well culture plates. Cell numbers were counted daily and graphed. The doubling time
was calculated based on growth curves and is shown in the table. (D) The indicated cell lines were infected with lentiviruses encoding shScrambled (shSCR) or
shDHX33. Whole-cell lysates were extracted 4 days postinfection and subjected to Western blot analysis with antibodies recognizing DHX33 and tubulin. (E)
shSCR or shDHX33-infected cells (104) from indicated cancer cell lines were plated onto 100-mm culture dishes. The cells were fixed 10 or 20 days later with
100% methanol and incubated with Giemsa stain for 1 h. Stained colonies were air dried and photographed. (F) shSCR or shDHX33-infected cells (104) from
Miapaca-2 and A549 cancer cells were subjected to cell cycle analysis by flow cytometry after propidium iodide staining.
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patients (3). Several drugs, including actinomycin D, cisplatin,
5-fluorouracil, and camptothecin have been shown to inhibit
RNA Pol I transcription (46–48). However, this field is still at the
early stage and will require more selective targets in order to de-
velop efficient therapeutic drugs that preferentially inhibit tumor
growth while sparing normal cells. Recently, selective drugs that
target rRNA synthesis have been developed, shedding a more pos-
itive light onto our ability to target rRNA synthesis as a way of
treating cancers. One of the latest compounds, CX-3543, is a small
molecule nucleolus-targeting agent that selectively disrupts
nucleolin/rDNA G-quadruplex complexes in the nucleolus (49).
CX-3543 inhibited Pol I transcription and induced apoptosis in
cancer cells and is currently in phase II clinical trials. Another
compound, CX-5461, selectively inhibits Pol I-driven relative to
Pol II-driven transcription, DNA replication, and mRNA transla-
tion (50). CX-5461 inhibits the initiation stage of rRNA synthesis
and induces both senescence and autophagy through a p53-inde-
pendent process in solid tumor cell lines. Although more work
needs to be done in order to develop efficient and more specific
drugs to target RNA Pol I transcription as a way for cancer treat-
ment, the validity of the approach itself has proven fruitful.
It seems uncertain whether other consensus targets of both
ARF and oncogenic RasV12 exist. However, given the pleiotropic
effects of ARF and Ras, identification of other common proteins
seems likely. In fact, given the large number of RNA helicases in
the DEAD/DEAH-box family, DHX33 may signal the first of
many dually regulated helicases. Given our findings that the heli-
case activity of DHX33 was required for the RasV12-driven pheno-
type, generating novel compounds that inhibit its helicase activity
seems a viable approach to prevent RasV12-induced transforma-
tion, especially in clinically relevant settings where Ras mutants,
and thus aberrant DHX33 expression, drive the disease.
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